GALECTO BIOTECH ApS: Financial statements 2020
CVR: 34878366
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
GALECTO BIOTECH ApS (CVR 34878366) has filed annual accounts for 2020. In 2020, the company reported a gross profit of EUR 4,883,512 and a net result of EUR 213,718 compared with EUR 323,877 the year before. That is an increase of 101.5% compared with the year before. Equity in the 2020 report amounted to EUR 2,904,076. The solvency ratio was 53.1%. The company had 16 employees in the financial year.
- Gross Profit
- EUR 4,883,512
- Profit/Loss
- EUR 213,718
- Equity
- EUR 2,904,076
- Total Assets
- EUR 5,467,239
- Employees
- 16
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | 4.9 mio. EUR | 214 t. EUR | 2.9 mio. EUR | 16 |
| 2019 | - | 2.4 mio. EUR | 324 t. EUR | 2.7 mio. EUR | 11 |
| 2018 | - | -2.6 mio. EUR | -3.7 mio. EUR | -12.8 mio. EUR | 5 |
| 2017 | - | -2.1 mio. EUR | -2.7 mio. EUR | -9.2 mio. EUR | 4 |
| 2016 | - | -1.3 mio. EUR | -1.8 mio. EUR | -6.5 mio. EUR | - |
How creditworthy is GALECTO BIOTECH ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of October 22, 2020, Hans Thalsgård Schambye has joined the board of directors of GALECTO BIOTECH ApS.
As of October 22, 2020, Jonathan Paul Freve has joined the board of directors of GALECTO BIOTECH ApS.
GALECTO BIOTECH ApS has published its annual report for 2019. Gross profit came to DKK 2,423,114, and the net result was DKK 323,877.
About GALECTO BIOTECH ApS
GALECTO BIOTECH ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Garrett Michael Winslow. The company is owned by Galecto Biotech AB. The company has 3 employees (2018). In 2025, the company reported a gross profit of EUR 1,039,275 and a net result of EUR -709,079 compared with EUR 310,297 the year before. Equity in the 2025 report amounted to EUR 7,844,625.